A cardiotonic steroid with anticancer activity
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Arenobufagin

Item No. 30695

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3β,5β,11α)-3,11,14-trihydroxy-12-oxo-bufa-20,22-dienolide
CAS Number
464-74-4
Molecular Formula
C24H32O6
Formula Weight
416.5
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 20 mg/mlDMSO:PBS (pH 7.2) (1:8): 0.11 mg/ml
λmax
299 nm
SMILES
O[C@H]1CC[C@@]2(C)[C@@](CC[C@]([C@]3(O)[C@@]4(C)[C@](C5=COC(C=C5)=O)([H])CC3)([H])[C@]2([H])[C@H](O)C4=O)([H])C1
InChi Code
InChI=1S/C24H32O6/c1-22-9-7-15(25)11-14(22)4-5-17-19(22)20(27)21(28)23(2)16(8-10-24(17,23)29)13-3-6-18(26)30-12-13/h3,6,12,14-17,19-20,25,27,29H,4-5,7-11H2,1-2H3/t14-,15+,16-,17-,19-,20+,22+,23+,24+/m1/s1
InChi Key
JGDCRWYOMWSTFC-AZGSIFHYSA-N
Origin
Plant/Bufonis Venenum
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $69

    Add

    5 mg

    $183

    Add

    10 mg

    $329

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Arenobufagin is a cardiotonic steroid that has been found in the skin secretions of the toad B. gargarizans and has anticancer activity.1,2,3,4 It inhibits Na+/K+-ATPase activity in isolated guinea pig ventricular myocytes with an IC50 value of 290 nM.1 Arenobufagin (20-500 nM) induces cleavage of poly(ADP-ribose) polymerase (PARP), caspase-3, and caspase-9, as well as induces apoptosis in HepG2 hepatocellular carcinoma cells.2 It inhibits proliferation of HepG2, Hep3B, BEL-7402, and MCF-7 cancer cells (IC50s = 101.9, 39.8, 416.3, and 143.7 nM, respectively), as well as multidrug-resistant HepG2/adm and MCF-7/adr cancer cells (IC50s = 730 and 67.5 nM, respectively). Arenobufagin (1 mg/kg once per day, i.v.) reduces tumor growth, the number and size of lung metastases, and tumor levels of the epithelial-to-mesenchymal transition (EMT) markers vimentin and β-catenin in a PC3 mouse xenograft model.3 Arenobufagin (5 and 10 µM/plug) inhibits VEGF-induced angiogenesis in a Matrigel™ plug assay in mice.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. dos Santos Cruz, J., and Matsuda, H. Arenobufagin, a compound in toad venom, blocks Na+-K+ pump current in cardiac myocytes. Eur. J. Pharmacol. 239(1-3), 223-226 (1993).

    2. Zhang, D.-M., Liu, J.-S., Deng, L.-J., et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/ mTOR pathway. Carcinogenesis 34(6), 1331-1342 (2013).

    3. Chen, L., Mai, W., Chen, M., et al. Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin. Pharmacol. Res. 123, 130-142 (2017).

    4. Li, M.W., S., Liu, Z., Zhang, W., et al. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem. Pharmacol. 83(9), 1251-1260 (2012).